KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Intangibles (2016 - 2025)

Astrazeneca (AZN) has 3 years of Intangibles data on record, last reported at $37.8 billion in Q4 2025.

  • For Q4 2025, Intangibles rose 1.8% year-over-year to $37.8 billion; the TTM value through Dec 2025 reached $37.8 billion, up 1.8%, while the annual FY2025 figure was $37.8 billion, 1.8% up from the prior year.
  • Intangibles reached $37.8 billion in Q4 2025 per AZN's latest filing, up from $37.2 billion in the prior quarter.
  • Across five years, Intangibles topped out at $37.8 billion in Q4 2025 and bottomed at -$32.3 billion in Q4 2023.
  • Average Intangibles over 3 years is $14.3 billion, with a median of $37.2 billion recorded in 2024.
  • Peak YoY movement for Intangibles: surged 215.22% in 2024, then rose 1.8% in 2025.
  • A 3-year view of Intangibles shows it stood at -$32.3 billion in 2023, then soared by 215.22% to $37.2 billion in 2024, then grew by 1.8% to $37.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $37.8 billion in Q4 2025, $37.2 billion in Q4 2024, and -$32.3 billion in Q4 2023.